| |
|
|
|
|
|
|
|||
|
Blood, 1 January 2007, Vol. 109, No. 1, pp. 383-385. Prepublished online as a Blood First Edition Paper on September 21, 2006; DOI 10.1182/blood-2006-05-025072.
TRANSPLANTATION Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning1 Washington University School of Medicine and St Louis Children's Hospital, MO; 2 Children's National Medical Center, Washington, DC; 3 Children's Hospital Medical Center, Cincinnati, OH; 4 Children's Mercy Hospital, Kansas City, MO
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a rare, fatal autoimmune disorder caused by mutations in the FOXP3 gene leading to the disruption of signaling pathways involved in regulatory T-lymphocyte function. Lifelong multiagent immunosuppression is necessary to control debilitating autoimmune manifestations such as colitis and food allergies. Allogeneic hematopoietic stem cell transplantation (HSCT) can restore T-cell regulatory function but has been previously associated with poor outcome. We describe successful HSCT in 4 patients with IPEX syndrome using a novel reduced-intensity conditioning regimen that resulted in stable donor engraftment, reconstitution of FOXP3+ T regulatory CD4+ cells, and amelioration of gastrointestinal symptoms.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2007 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||